Loading clinical trials...
Loading clinical trials...
A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence
Conditions
Interventions
UGN-102
Locations
19
United States
Mayo Clinic Cancer Center
Phoenix, Arizona, United States
Arkansas Urology
Little Rock, Arkansas, United States
Loma Linda University
Loma Linda, California, United States
Providence Medical Institute
Santa Monica, California, United States
Clinical Research Center of Florida
Pompano Beach, Florida, United States
John Hopkins University
Baltimore, Maryland, United States
Start Date
October 15, 2018
Primary Completion Date
January 3, 2020
Completion Date
October 21, 2020
Last Updated
September 16, 2022
NCT05889195
NCT06257264
NCT07206225
NCT06857175
NCT04693377
NCT06770582
Lead Sponsor
UroGen Pharma Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions